According to Supernus Pharmaceuticals 's latest financial reports the company's current revenue (TTM) is $0.60 B. In 2022 the company made a revenue of $0.66 B an increase over the years 2021 revenue that were of $0.57 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.60 B | -8.95% |
2022 | $0.66 B | 15.09% |
2021 | $0.57 B | 11.41% |
2020 | $0.52 B | 32.5% |
2019 | $0.39 B | -3.95% |
2018 | $0.40 B | 35.29% |
2017 | $0.30 B | 40.57% |
2016 | $0.21 B | 46.83% |
2015 | $0.14 B | 58.75% |
2014 | $92.24 M | 667.42% |
2013 | $12.02 M | 712.71% |
2012 | $1.47 M | -116.28% |
2011 | -$9.09 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $93.02 B | 15,211.73% | ๐บ๐ธ USA |
Abbott Laboratories ABT | $40.10 B | 6,502.08% | ๐บ๐ธ USA |
Eli Lilly LLY | $34.12 B | 5,516.94% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $45.00 B | 7,308.14% | ๐บ๐ธ USA |
Zogenix ZGNX | $81.69 M | -86.55% | ๐บ๐ธ USA |
United Therapeutics UTHR | $2.32 B | 283.11% | ๐บ๐ธ USA |